Malaria
Conditions
Keywords
Antimalarial Drug Resistance
Brief summary
Annually, malaria affects an estimated 229 million people, causing 409,000 deaths (WHO 2019) mostly in Africa. Despite a substantial decline in malaria-related maternal and child deaths in recent years, progress in controlling malaria has been slower than anticipated and uneven across countries. COVID-19-related disruption of malaria control activities will likely further slow the pace and lead to an even greater burden in the near future. One of the greatest challenges delaying progress in malaria elimination is antimalarial drug resistance. Recent reports of the emergence of artemisinin-resistant parasites in parts of Africa are the cause of even greater concern, since the loss of frontline treatment efficacy could bring about a dramatic reversal of progress. Large-scale genetic surveillance of Plasmodium is an effective tool for rapid detection of changes in drug efficacy, enabling countries to switch to effective preventive and curative treatments when necessary. The implementation of genetic surveillance has proven very successful in small, low malaria burden countries. However, in large, high malaria burden countries such implementation is operationally and economically more complex. Screening pregnant women attending Antenatal Care (ANC) services can be a practical and economical strategy for estimating malariometric parameters, with fewer limitations and challenges than conventional survey methodologies in children. The present study aims to demonstrate that this is also true for the genetic surveillance of antimalarial drug resistance.
Interventions
OTHERMalaria screening
Participants are screened for malaria and a dried blood spot is collected from malaria positive cases
Sponsors
Kinshasa School of Public Health
Wellcome Sanger Institute
University of Oxford
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Pregnancy OR for children age \<14 years old and in primary school
Exclusion criteria
* Refusal to participate (i.e., consent is not given by the participant for women or by the parents in the case of children)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the frequency of Plasmodium falciparum mutations associated with antimalarial drug resistance in the population of pregnant women with that of children. | 18 months | Plasmodium falciparum from infected individuals will be sequenced and the frequency of antimalarial drug resistance mutations in pregnant women will be compared with that of children. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the acceptability of the intervention | 12 months | Acceptability will be measured as: 1) the number of women who agree to be tested for malaria, over the number of women who attend the ANC service and 2) via a specially designed questionnaire. |
| Compare malaria prevalence in pregnant women with that of in children throughout the year. | 12 months | Malaria prevalence will be measured by Rapid Diagnostic Test and standard malaria microscopy in both populations (pregnant women and children) for a period of 12 months and results compared. |
Countries
Democratic Republic of the Congo
Outcome results
None listed